BackgroundCheck.run
Search For

Paul K Laikind, 69Park City, UT

Known as:
Paul Kevin Dr Laikind Paul Te Laikind Paul K Stenneslaikind Paul Laikand Paul D
Related to:
Summer J Phillips 54 Virginia Harris 73 Geraldine M Stennes 83 Petra C Krismer 46 Mark S Harris 70 Paul M Stennes 85 George K Lingenbrink 62 Jessica L Harris 39 Lara Lingenbrink 29 Dawn M Stennes 55 Margaret A Harris 68 Georg Lingenbrink Jeanne Harris Lisa M Stennes 59 Nora Harrison Nora Harris 72 Eric Harris 48 Adrienne N Harris 65 Phyllis M Harris 97

Paul Laikind Phones & Addresses

Park City, UT   

12536 Grevillea Pl, San Diego, CA 92130   

1316 Santa Barbara St, San Diego, CA 92107   

500 Harbor Dr, San Diego, CA 92101   

Coalville, UT   

Summit, UT   

Get Report
Control this profile

Mentions for Paul K Laikind

Paul Laikind resumes & CV records

Resumes

Paul Laikind Photo 5

Paul Laikind

Location:
Greater San Diego Area
Industry:
Biotechnology
Paul Laikind Photo 6

Paul Laikind

Publications & IP owners

Us Patents

Method For Inhibiting Human Tumor Cells

US Patent:
6410326, Jun 25, 2002
Filed:
Jun 7, 1995
Appl. No.:
08/486683
Inventors:
Harry E. Gruber - San Diego CA
Douglas J. Jolly - La Jolla CA
James G. Respess - San Diego CA
Paul K. Laikind - San Diego CA
Jack R. Barber - San Diego CA
Daniel C. St. Louis - Rockville MD
Sunil D. Chada - Vista CA
Stephen M. W. Chang - San Diego CA
John F. Warner - San Diego CA
Assignee:
Chiron Corporation - Emeryville CA
International Classification:
C12N 1563
US Classification:
435455
Abstract:
Recombinant retroviruses carrying a vector construct capable of preventing, inhibiting, stabilizing or reversing infectious, cancerous or auto-immune diseases are disclosed. More specifically, the recombinant retroviruses of the present invention are useful for (a) stimulating a specific immune response to an antigen or a pathogenic antigen; (b) inhibiting a function of a pathogenic agent, such as a virus; and (c) inhibiting the interaction of an agent with a host cell receptor. In addition, eucaryotic cells infected with, and pharmaceutical compositions containing such a recombinant retrovirus are disclosed. Various methods for producing recombinant retroviruses having unique characteristics, and methods for producing transgenic packaging animals or insects are also disclosed.

Chimeric Gene Constructs

US Patent:
6495349, Dec 17, 2002
Filed:
Jun 5, 1995
Appl. No.:
08/462512
Inventors:
Harry E. Gruber - Rancho Santa Fe CA, 92067
Douglas J. Jolly - Leucadia CA, 92024
James G. Respess - San Diego CA, 92109
Paul K. Laikind - San Diego CA, 92103
International Classification:
C12N 15867
US Classification:
435 911, 4353201, 435325, 435366, 435 914, 435 9151, 435455, 435456, 536 231, 536 232, 536 235, 536 2372, 536 241
Abstract:
Recombinant retroviruses carrying a vector construct capable of preventing, inhibiting, stabilizing or reversing infectious, cancerous or auto-immune diseases are disclosed. More specifically, the recombinant retroviruses of the present invention are useful for (a) stimulating a specific immune response to an antigen or a pathogenic antigen; (b) inhibiting a function of a pathogenic agent, such as a virus; and (c) inhibiting the interaction of an agent with a host cell receptor. In addition, eucaryotic cells infected with, and pharmaceutical compositions containing such a recombinant retrovirus are disclosed. Various methods for producing recombinant retroviruses having unique characteristics, and methods for producing transgenic packaging animals or insects are also disclosed.

Method For Making Reflection Defective Retroviral Vectors For Infecting Human Cells

US Patent:
5856185, Jan 5, 1999
Filed:
Jun 7, 1995
Appl. No.:
8/472109
Inventors:
Harry E. Gruber - San Diego CA
Douglas J. Jolly - La Jolla CA
James G. Respess - San Diego CA
Paul K. Laikind - San Diego CA
Jack R. Barber - San Diego CA
Daniel C. St. Louis - Rockville MD
Sunil D. Chada - Vista CA
Stephen M. W. Chang - San Diego CA
John F. Warner - San Diego CA
Assignee:
Chiron Corporation - Emeryville CA
International Classification:
C07H 2104
C12N 510
C12N 1548
US Classification:
435372
Abstract:
Recombinant retroviruses carrying a vector construct capable of preventing, inhibiting, stabilizing or reversing infectious, cancerous or auto-immune diseases are disclosed. More specifically, the recombinant retroviruses of the present invention are useful for (a) stimulating a specific immune response to an antigen or a pathogenic antigen; (b) inhibiting a function of a pathogenic agent, such as a virus; and (c) inhibiting the interaction of an agent with a host cell receptor. In addition, eucaryotic cells infected with, and pharmaceutical compositions containing such a recombinant retrovirus are disclosed. Various methods for producing recombinant retroviruses having unique characteristics, and methods for producing transgenic packaging animals or insects are also disclosed.

Methods Of Preventing Tissue Damage Associated With Decreased Blood Flow By Administration Of Aica Riboside Compounds

US Patent:
5817640, Oct 6, 1998
Filed:
May 16, 1995
Appl. No.:
8/443245
Inventors:
Harry E. Gruber - Rancho Santa Fe CA
Kevin M. Mullane - Del Mar CA
Paul K. Laikind - San Diego CA
Assignee:
Gensia Pharmaceuticals - San Diego CA
International Classification:
A61K 3170
US Classification:
514 46
Abstract:
Methods of preventing tissue damage associated with decreased blood flow in a human by administering AICA riboside or a prodrug thereof in an amount which provides a blood plasma concentration of between 1. mu. g/ml and 20. mu. g/ml of AICA riboside for a time sufficient to reduce the risk of said tissue damage in said human. Methods of preventing an adverse clinical outcome, such as an adverse cardiovascular and/or cerebrovascular event, in a patient at risk for such outcome by administering AICA riboside or a prodrug thereof in an amount which provides a blood plasma concentration of between 1. mu. g/ml and 20. mu. g/ml of AICA riboside for a time sufficient to reduce the risk for said patient.

Method For Destroying A Diseased Human Cell

US Patent:
5830458, Nov 3, 1998
Filed:
Jun 7, 1995
Appl. No.:
8/487776
Inventors:
Harry E. Gruber - Rancho Santa Fe CA
Douglas J. Jolly - Leucadia CA
James G. Respess - San Diego CA
Paul K. Laikind - San Diego CA
International Classification:
A61K 4800
US Classification:
424 932
Abstract:
Recombinant retroviruses carrying a vector construct capable of preventing, inhibiting, stabilizing or reversing infectious, cancerous or auto-immune diseases are disclosed. More specifically, the recombinant retroviruses of the present invention are useful for (a) stimulating a specific immune response to an antigen or a pathogenic antigen; (b) inhibiting a function of a pathogenic agent, such as a virus; and (c) inhibiting the interaction of an agent with a host cell receptor. In addition, eucaryotic cells infected with, and pharmaceutical compositions containing such a recombinant retrovirus are disclosed. Various methods for producing recombinant retroviruses having unique characteristics, and methods for producing transgenic packaging animals or insects are also disclosed.

Recombinant Retroviruses

US Patent:
5716613, Feb 10, 1998
Filed:
Jun 7, 1995
Appl. No.:
8/474736
Inventors:
Harry E. Guber - San Diego CA
Douglas J. Jolly - La Jolla CA
James G. Respess - San Diego CA
Paul K. Laikind - San Diego CA
Assignee:
Chiron Viagene, Inc.
International Classification:
A61K 4800
C12N 1586
US Classification:
424 932
Abstract:
Recombinant retroviruses carrying a vector construct capable of preventing, inhibiting, stabilizing or reversing infectious, cancerous or auto-immune diseases are disclosed. More specifically, the recombinant retroviruses of the present invention are useful for (a) stimulating a specific immune response to an antigen or a pathogenic antigen; (b) inhibiting a function of a pathogenic agent, such as a virus; and (c) inhibiting the interaction of an agent with a host cell receptor. In addition, eucaryotic cells infected with, and pharmaceutical compositions containing such a recombinant retrovirus are disclosed. Various methods for producing recombinant retroviruses having unique characteristics, and methods for producing transgenic packaging animals or insects are also disclosed.

Replication Defective Viral Vectors For Infecting Human Cells

US Patent:
6133029, Oct 17, 2000
Filed:
Jun 6, 1995
Appl. No.:
8/479672
Inventors:
Harry E. Gruber - San Diego CA
Douglas J. Jolly - La Jolla CA
James G. Respess - San Diego CA
Paul K. Laikind - San Diego CA
Assignee:
Chiron Corporation - Emeryville CA
International Classification:
C12N 510
US Classification:
435366
Abstract:
Recombinant retroviruses carrying a vector construct capable of preventing, inhibiting, stabilizing or reversing infectious, cancerous or auto-immune diseases are disclosed. More specifically, the recombinant retroviruses of the present invention are useful for (a) stimulating a specific immune response to an antigen or a pathogenic antigen; (b) inhibiting a function of a pathogenic agent, such as a virus; and (c) inhibiting the interaction of an agent with a host cell receptor. In addition, eucaryotic cells infected with, and pharmaceutical compositions containing such a recombinant retrovirus are disclosed. Various methods for producing recombinant retroviruses having unique characteristics, and methods for producing transgenic packaging animals or insects are also disclosed.

Recombinant Retroviruses

US Patent:
5851529, Dec 22, 1998
Filed:
Jun 7, 1995
Appl. No.:
8/477890
Inventors:
Harry E. Guber - San Diego CA
Douglas J. Jolly - La Jolla CA
James G. Respess - San Diego CA
Paul K. Laikind - San Diego CA
International Classification:
A61K 3921
A61K 3900
A61K 4800
US Classification:
4241881
Abstract:
Recombinant retroviruses carrying a vector construct capable of preventing, inhibiting, stabilizing or reversing infectious, cancerous or auto-immune diseases are disclosed. More specifically, the recombinant retroviruses of the present invention are useful for (a) stimulating a specific immune response to an antigen or a pathogenic antigen; (b) inhibiting a function of a pathogenic agent, such as a virus; and (c) inhibiting the interaction of an agent with a host cell receptor. In addition, eucaryotic cells infected with, and pharmaceutical compositions containing such a recombinant retrovirus are disclosed. Various methods for producing recombinant retroviruses having unique characteristics, and methods for producing transgenic packaging animals or insects are also disclosed.

Possible Relatives

Daniel A Laikind  Paul M Johnson  Paul Stamps  Paul B Stanaway  Paul Stanczyk  Paul L Standefer  Paul F Stander  Paul A Standiford  Paul R Johnston  Paul A Standring 

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.